Indian Immunologicals to invest Rs 75 crore for viral antigen manufacturing plant in Telangana
The company plans to utilise the facility to manufacture COVID-19 vaccines post completion of its R&D with Griffith University, Australia, IIL added.
New Delhi: Biologicals firm Indian Immunologicals Ltd (IIL) on Wednesday said it will invest Rs 75 crore to commission a new viral antigen manufacturing facility in Telangana to increase its capacity for supplying vaccines.
The new facility will be specially designed as a multi-product facility and cater to the need for viral vaccines in the pipeline, including for dengue, zika and varicella, IIL said in a statement.
"This facility has been specially designed to cater to the need for various viral vaccines and it will boost our manufacturing capacity by 35 percent. The new plant is expected to be ready for operation by October 2021," IIL Deputy MD Prasanna Deshpande said.
IIL exports various human and animal vaccines to over 50 countries and currently employs around 1,300 people.
Read also: Indian Immunologicals launches classical swine fever vaccine under Brand name 'Raksha Class'
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.